Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Key Stats

• Today's Range: $8.10 to $8.99
• 50-Day Range: $5.66 to $9.09
• 52-Week Range: $5.47 to $11.99
• Volume: 13,755 shs
• Average Volume: 68,649 shs
• Market Capitalization: $169.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Buy

Actuate Therapeutics Stock Analysis - MarketRank™

Actuate Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 538th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Actuate Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Actuate Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Actuate Therapeutics has a P/B Ratio of 828.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACTU.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actuate Therapeutics does not currently pay a dividend.

Dividend Growth

Actuate Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ACTU.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Actuate Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Actuate Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ACTU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Actuate Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,988.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

69.34% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

ACTU Stock Analysis - Frequently Asked Questions

How have ACTU shares performed this year?

Actuate Therapeutics' stock was trading at $7.96 on January 1st, 2025. Since then, ACTU shares have increased by 4.1% and is now trading at $8.2860.

How were Actuate Therapeutics' earnings last quarter?

Actuate Therapeutics, Inc. (NASDAQ:ACTU) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06.

When did Actuate Therapeutics IPO?

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering (IPO) on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Who are Actuate Therapeutics' major shareholders?

Top institutional investors of Actuate Therapeutics include BIOS Capital Management LP (48.68%), Voss Capital LP (1.40%), Geode Capital Management LLC (0.58%) and Gleason Group Inc. (0.10%). Insiders that own company stock include Todd S Thomson, Leslie W Kreis, Equity Cof Lp Bios and Aaron GL Fletcher.
View institutional ownership trends.

How do I buy shares of Actuate Therapeutics?

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Actuate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACTU
• Previous Symbol: NASDAQ:ACTU
• CIK: 1652935
• Web: N/A
• Phone: (847) 986-4190
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Actuate Therapeutics: $20.50
• High Price Target: $21.00
• Low Price Target: $20.00
• Potential Upside/Downside: +145.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.28 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -339.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.46
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.01 per share
• Price / Book: 835.00

Miscellaneous

• Outstanding Shares: 20,471,000
• Free Float: 6,276,000
• Market Cap: $170.93 million
• Optionable: N/A
• Beta: N/A